Cover Image

Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.

<h4>Background</h4>Onchocerciasis ("river blindness"), is a neglected tropical disease caused by the filarial nematode Onchocerca volvulus and transmitted to humans through repeated bites by infective blackflies of the genus Simulium. Moxidectin was approved by the United State...

Full description

Saved in:

Bibliographic Details
Main Authors:	Beesan Tan (Author), Nicholas Opoku (Author), Simon K Attah (Author), Kwablah Awadzi (Author), Annette C Kuesel (Author), Janis Lazdins-Helds (Author), Craig Rayner (Author), Victoria Ryg-Cornejo (Author), Mark Sullivan (Author), Lawrence Fleckenstein (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.
by: Kwablah Awadzi, et al.
Published: (2014)

Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus.
by: Mike Y Osei-Atweneboana, et al.
Published: (2011)

Multimodal biomarker discovery for active Onchocerca volvulus infection.
by: Ole Lagatie, et al.
Published: (2021)

Active infection with Onchocerca volvulus and the linkage to epilepsy/nodding syndrome.
by: Kathrin Arndts, et al.
Published: (2024)

Active infection with Onchocerca volvulus and the linkage to epilepsy/nodding syndrome
by: Kathrin Arndts, et al.
Published: (2024)

Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment.
by: Catherine Bourguinat, et al.
Published: (2007)

Ivermectin resistance in Onchocerca volvulus: toward a genetic basis.
by: Sara Lustigman, et al.
Published: (2007)

Interruption of transmission of Onchocerca volvulus in the Southern Chiapas Focus, México.
by: Mario A Rodríguez-Pérez, et al.
Published: (2013)

Establishment of an in vitro culture system to study the developmental biology of Onchocerca volvulus with implications for anti-Onchocerca drug discovery and screening.
by: Narcisse V T Gandjui, et al.
Published: (2021)

Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection.
by: Didier Bakajika, et al.
Published: (2022)

Successful interruption of transmission of Onchocerca volvulus in the Escuintla-Guatemala focus, Guatemala.
by: Rodrigo J Gonzalez, et al.
Published: (2009)

Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West Africa.
by: Simon J O'Hanlon, et al.
Published: (2016)

A four-antigen mixture for rapid assessment of Onchocerca volvulus infection.
by: Peter D Burbelo, et al.
Published: (2009)

The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation.
by: Nolan D Wood, et al.
Published: (2024)

Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity.
by: Stephen R Doyle, et al.
Published: (2017)

Development of Onchocerca volvulus in humanized NSG mice and detection of parasite biomarkers in urine and serum.
by: John B Patton, et al.
Published: (2018)

A Recombinant Positive Control for Serology Diagnostic Tests Supporting Elimination of Onchocerca volvulus.
by: Allison Golden, et al.
Published: (2016)

Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation.
by: Robert Colebunders, et al.
Published: (2021)

Geospatial modeling of pre-intervention nodule prevalence of Onchocerca volvulus in Ethiopia as an aid to onchocerciasis elimination.
by: Himal Shrestha, et al.
Published: (2022)

Identification of three immunodominant motifs with atypical isotype profile scattered over the Onchocerca volvulus proteome.
by: Ole Lagatie, et al.
Published: (2017)

Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis.
by: Shabnam Jawahar, et al.
Published: (2021)

Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naïve and a multiply treated population from Cameroon.
by: Sébastien D S Pion, et al.
Published: (2013)

Oligonucleotide based magnetic bead capture of Onchocerca volvulus DNA for PCR pool screening of vector black flies.
by: Hemavathi Gopal, et al.
Published: (2012)

Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial.
by: Joseph D Turner, et al.
Published: (2010)

Nodding syndrome, a case-control study in Mahenge, Tanzania: Onchocerca volvulus and not Mansonella perstans as a risk factor.
by: Luís-Jorge Amaral, et al.
Published: (2023)

Optimized strategy for real-time qPCR detection of Onchocerca volvulus DNA in pooled Simulium sp. blackfly vectors.
by: Mary Doherty, et al.
Published: (2023)

The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
by: Fidelis Cho-Ngwa, et al.
Published: (2010)

Factors Associated with Ivermectin Non-Compliance and Its Potential Role in Sustaining Onchocerca volvulus Transmission in the West Region of Cameroon.
by: Laura Senyonjo, et al.
Published: (2016)

Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naïve and a frequently treated population from Cameroon.
by: Hugues C Nana-Djeunga, et al.
Published: (2014)

Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis.
by: Yashpal S Chhonker, et al.
Published: (2023)

The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice.
by: Jessica A Hess, et al.
Published: (2016)

Identification and characterization of the Onchocerca volvulus Excretory Secretory Product Ov28CRP, a putative GM2 activator protein.
by: Ferdinand Ngale Njume, et al.
Published: (2019)

Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study
by: Michel Mandro, et al.
Published: (2018)

Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo.
by: Saskia I Johanns, et al.
Published: (2022)

Ongoing Transmission of Onchocerca volvulus after 25 Years of Annual Ivermectin Mass Treatments in the Vina du Nord River Valley, in North Cameroon.
by: Albert Eisenbarth, et al.
Published: (2016)

Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo
by: Saskia I. Johanns, et al.
Published: (2022)

Prospects for Moxidectin as a New Oral Treatment for Human Scabies.
by: Kate E Mounsey, et al.
Published: (2016)

Preliminary evaluations of 3-dimensional human skin models for their ability to facilitate in vitro the long-term development of the debilitating obligatory human parasite Onchocerca volvulus.
by: Christoph Malkmus, et al.
Published: (2020)

Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.
by: Mohammed A K Mahdy, et al.
Published: (2018)

Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.
by: Parakkal Jovvian George, et al.
Published: (2019)